
mutations
strains
rifampicin
susceptibility
rifampicin resistance
isoniazid resistance
rapid detection
assay
gene
pcr
identification
katg
ethambutol resistance
ethambutol
resistance
expression
fluoroquinolone resistance
sensitivity
system
clinical specimens
complex
molecular characterization
polymorphism
genotype
evolution
specimens
performance
resistant
infection
diagnosis
epidemiology
molecular epidemiology
transmission
prevalence
south-africa
treatment outcomes
metaanalysis
xdr-tb
therapy
chemotherapy
efficacy
disease
model
emergence
multicenter
culture
sputum
india
china
beijing genotype
genetic diversity
database
spread
family
genotype
global
western-cape
new-york
russia
patterns
outbreak
surveillance
exogenous reinfection
nosocomial transmission
epidemics
risk-factors
short-course chemotherapy
hiv-infection
management
outcomes
impact
risk
hiv
antiretroviral therapy
community-based
community
population
trends
reinfection
africa
dots
hiv-infected patients
cohort
program
health
adherence
default
follow-up
infected patients
patient
burden
treatment failure
peru
lima
childhood tb
treatment
predictors
mortality
children
care
moxifloxacin
pharmacokinetics
fluoroquinolones
pyrazinamide
ofloxacin
interferon-gamma
immune-responses
in-vitro
bactericidal activity
gatifloxacin
murine model
in-vitro activity
bedaquiline
early bactericidal activity
delamanid
dots-plus
survival
tolerance
prevention
regimens
sputum culture conversion
adults
elimination
experience
positive pulmonary tb
household
challenges
clinical features
contacts
young children
community
cost
implementation
feasibility
close contacts
netherlands
malawi
surgery
controlled trial
meropenem/clavulanate-containing regimens
gentamicin
compassionate use
aminoglycosides
hearing-loss
safety
hiv infected adults
preventive therapy
update
infectious diseases
clinical trial
taiwan
future prospects
acid-fast bacilli
public health
pakistan
bacilli
time
addis-ababa
classification
dynamics
fragment-length-polymorphism
molecular epidemiology
genomic deletions
rapid diagnosis
drug-susceptibility assay
sputum smears
1st-line
2nd-line
multidrug
contacts
developing countries
health-care workers
strategies
prison
tanzania
shanghai
area
patients
immigration
province
south-india
mdr
thailand
nation
mellitus
western cape province
commendations
gastric lavage
latent tb
social determinants
women
city
rural china
standard retreatment regimen
retreatment
settings
cape-town
guidelines
latvia
standardized regimen
culture conversion
randomized controlled trial
adverse events
mdr-tb treatment
challenges
household
clinical features
contacts
young children
childhood tb
treatment
lima
impact
europe
rural south-africa
era
health system
cost-effectiveness
resource-limited settings
diabetes
risk
barriers
strategy
control
mixed infection
state
kenya
isoniazid-preqative pulmonary tb
death
rates
depression
diatric tb
peru
physicians
treatment failure
burden
recurrence
relapse
reinfection
human-immunodeficien
united-states
philippines
exposure
failure
sub-saharan africa
antiretroviral therapy
hiv
community-based
prospective cohort
active antiretroviral therapy
directly observed therapy
predictors
patient
hiv-infected patients
cohort
children
mortality
care
russian federation
interventions
adherence
default
follow-up
infected patients
health
program
dots
africa
burden
recurrence
relapse
reinfection
community
trends
population
outbreak
surveillance
exogenous reinfection
nosocomial transmission
epidemics
risk-factors
short-course chemotherapy
hiv-infection
management
outcomes
impact
risk
hiv
antiretroviral therapy
community-based
patterns
prevalence
health-care workers
developing countries
strategies
prison
russia
south-africa
treatment outcomes
metaanalysis
xdr-tb
prevention
regimens
sputum culture conversion
adults
elimination
experience
positive pulmonary tb
household
challenges
clinical features
contacts
young children
childhood tb
treatment
lima
peru
predictors
mortality
children
care
cohort
program
health
adherence
default
follow-up
infected patients
patient
burden
recurrence
relapse
reinfection
africa
dots
hiv-infected patients